

Index

- AB toxins, 63
 CNF, 39
 CNF, DNT, 43
- Actin
 Actin ring and bone resorption, 151
 ADP-ribosylation by C2, 68
 Bartonella and, 92
 Calponin, 35
 Cytoskeleton and Rho family, 33–34
 Myosin light chain, 15
 PMT and, 15
 Rho and, 14
- Acting
 Activation by YpkA, 131
- Actinobacillus actinomycetemcomitans*
 CDT, 59, 64
- ADAM metalloprotease disintegrin, 178
 Expression in gastric cancer, 179
- Adenoma
 Colorectal cancer and adenoma formation,
 211–213
- ADP ribosylation
 Activity of ExoS, 126
 By C2, 68
- Aflatoxin, 201
 Hepatitis B virus carriers and liver
 carcinoma, 201
- AIDS
 Bartonella in AIDS patients, 83
- Akt/PKB
 Activation by RANKL, 150
- Alkaline phosphatase, 149
 Down regulation by PMT, 157
- Anchorage-independent growth
 PMT and, 17
- Angiogenesis
 Bartonella, effects on, 83–84
- Animal models
 Carcinogens, 204
 Helicobacter, 171–172, 174–175
- Anticarcinogens
 Bacterial, 205–206
- AP-1
 Activation by *Bartonella*, 98
- Apoptosis
 CNF, 45
 Helicobacter induced, 171
 Helicobacter LPS induced, 174
 PMT and, 20
 Shigella IpaB induced, 134
 Toxin involvement in, 7
 Type III effectors and, 132
- Arp2/3
 WASP, 35
- Atrophic rhinitis, 155
- Bacillary angiomatosis, 82
- Bacteria
 Bladder cancer and, 206–207
 Carcinogen production, 200–205
 Stomach cancer linked to bacterial
 overgrowth, 209–211

- Bacteroides*
 Glycosidase activity, 205
- Bartonella*, 81–108
 Apoptosis, 106–107
 Cell binding, 84–85
 Cell motility, 99–100
 Disease caused by, 82–83
 Disease in cats, 82
 Effects on angiogenesis, 83–84
 Endothelial cells and, 90–92
 Erythrocytes and, 86–90
 Life cycle, 82
 Perinuclear location, 97
 Porins, 85–86
 Proliferation, 106–107
 Rho and, 92–95, 96, 98
 TFSS, 95
 Upregulation of E-selectin, 108
 Uptake, 95–96
 VEGF, 104
 VEGF similarity, 100–101, 106
- Bile acid metabolites
 Cancer linked to, 203–204
- Bilharzial infection
 Bladder cancer and, 207
- Bladder cancer, 206
- Blebs
Bartonella, 86
- Bombesin, 12, 13
- Bone, 147–162
 Dynamics, 147, 151
 Remodelling, 152–153
 Resorption, 151–152
 Toxins and Rho, 153–162
- Bordetella*, 42
 Atrophic rhinitis, 25
 DNT, 33
- Breast cancer
 Phytoestrogen protection against, 205
- Brucella*, 95
- Burkholderia pseudomallei*
 TTSS,
- C2 toxin, 68
- C3 toxin, 3, 154, 157
 Action on Rho, 37–38
- Campylobacter*
 CDT, 64
- Cancer
 Bacterially induced, 4, 199–219
 ErbB2 overexpression, 58–59
Helicobacter induction of, 169
 Molecular mechanisms of, 200
- Carcinogen
Helicobacter as, 169
- Carcinogenesis
 Stages in, 200
- Carrion's disease, 81, 86
- Cat scratch disease, 82
 Differential diagnosis, 105
- cbfa-1, 149
 Down regulation by PMT, 157
- CDC25 phosphatase
 CNF effect on, 59
- Cdc42, 18, 33, 36
 Introduction, 14
- Cell adhesion molecules
Bartonella and, 91
- Cell cycle, 55–59
 Control by CDTs, 65
- Cell scattering
Helicobacter induction of, 179
- Cellular Microbiology, iii, 53
- Chemokines
Helicobacter activation of, 172
- Chronic infection
 Cancer and, 169
 Linked to inflammation, 4
- CIF, 68, 228
- Circular dichroism (CD), 10, 23
- Citrobacter rodentium*
 CIF, 68
- Citron kinase, 37
- Clinical studies
Helicobacter, 170
- Clostridium difficile*
 Osteoclasts treated with toxin, 161
 Toxins, 154
 Toxins and Rho, 38

Cambridge University Press
 052182091X - Bacterial Protein Toxins: Role in the Interference with Cell Growth Regulation

Edited by Alistair J Lax

Index

[More information](#)

- Clostridium novyi*
 Toxin and Rho, 38
 Toxins, 154
- Clostridium sordellii*
 Osteoclasts treated with toxin, 161
 Toxins, 154
 Toxins and Rho, 38
- c-Met receptor tyrosine kinase, 180–181
- Collagen, 148
- Colorectal cancer
 Bacteria and, 211–213
- c-src*
 Activation by RANKL, 150
- Cycasin
 Carcinogen, 204
- Cyclic AMP
Helicobacter activation of, 176
- Cyclin-Dependent Kinases, 55
- Cyclins, 55, 58
 PMT and, 20
 Rac, 36
- Cyclooxygenase-2 (COX-2)
 CNF stimulates, 42, 207
Helicobacter activation, 185
Helicobacter induction of, 175
 MAPK activation of, 176
- Cyclostatins, 53–74
 Definition, 73
 Experimental approaches, 70–73
- Cytokines
 Bone resorption, 147, 151
- Cytolethal Distending Toxin, 53–74
- Cytolethal Distending Toxin (CDT)
 CDT-B, 60–62
 CDT-B target, 61–62
 CDT-C, 62
 Colonisation by bacteria expressing, 64
 DNA damage, 59–60
 Effect on CDC25 phosphatase, 59
 In vivo relevance, 63–65
 Introduction, 53, 58–59
- Cytotoxic Necrotizing Factor (CNF), 68, 154, 229
 Apoptosis, 45
 Cancer and, 45
 Catalysis, 41, 44
 COX-2 activation of, 42
 Disease linked to, 44–45
E. coli urinary tract infection, 207
 Introduction, 33
 Lethality of, 39
 Mode of action of, 40–41
 Multinucleation caused by, 41
 PMT homology, 22
 Structure of, 39–40, 41, 43–44
 Uptake, 39
- Deamidation
 Of Rho by CNF, 40–41
 Of Rho by DNT, 42
- Dermonecrotic toxin (DNT)
 Bone loss due to, 155
 Catalysis, 44
 Disease linked to, 45, 154, 228
 Effects on bone, 45
 Introduction, 33
 Multinucleation caused by, 42
 Rho activation, 42–43
 Structure, 43–44
- Diaphanous, 34, 37
- Differentiation
 PMT inhibition of, 25
- DNA
 CDT target, 61–62
- E. coli*
 Cif, 228
 EspF and cell death, 135
 Type III effector, 128
- Endotoxin
 Bone resorption and, 147
- EPEC
 Tir effector, 128
- Epidermal Growth Factor (EGF)
 Cell cycle and, 58

- Epidermal Growth Factor (EGF) receptors
Action by SAGP, 69
Helicobacter activation of, 177–179
PMT activation and, 19
Transactivation independent of *Helicobacter cag*, 178
- ErbB-2
Helicobacter activation, 179
- ERK1, 132
- ERKs, 18
And cell cycle, 58
And PMT, 18–19
- Escherichia coli*
Bladder infection, 207
CDT, 59, 64
CIF, 68
CNF, 33
STa, 69
TTSS, 117
- E-selectin, 91
- F. nucleatum* immunosuppressive protein (FIP), 69
- Fas
Helicobacter, 183
- Fibronectin, 151
- Focal adhesion kinase
Activation by CNF, 41
Activation by PMT, 15
- Gallbladder
Cancer, 213–215
Cancer link with gallstone, 214
- GAP activity
ExoS, 127
- Gastrin
Elevation due to *Helicobacter*, 172
- Gender differences
Response to *Helicobacter*, 172
- Glucosides
Plant glucoside metabolism, 204
- Glucosylation
Of Rho proteins, 38
- Glycosides
Conjugates as carcinogens, 204–205
- G-proteins
Activation of Rho, 14
G₁₂ family and PMT, 21
G_q, 156
G_q activation by PMT, 13–14, 18, 21
G_q activation of PLC- β , 12
Introduction, 11–12
- GTPase activating proteins (GAPs), 33
- Guanine nucleotide exchange factors (GEFs), 33
- Guanylyl cyclase
STa, 69
- Haemolytic and uraemic syndrome (HUS)
VT, 69
- Haemophilus ducreyi*
CDT, 59, 64
- Helicobacter*, 169–186
Animal models, 171, 174–175
Animal models with *H. felis*, 171–172
Animal models with *H. mustelae*, 171
Apoptosis, 183–185
cag, 172–173
cag and c-Fos, 184
CagA and cancer, 182
CagA interaction with PLC γ , 181
CagA target, 181
Cancer, 4, 208–209
CDT, 64
Cell scattering, 179
c-Met, 180–182
COX-2 activation, 175, 185
Effects on cell lines, 173
EGF receptor activation, 177–179
Eradication, 170
Gastric cancer, 207
Host factor involvement, 182–185
Induction of proliferation *in vivo*, 173–174
Infection linked to blood group antigen *babA2*, 173–174
MAPK activation, 182
Mongolian gerbil animal model, 174
NF- κ B, 174
Oesophageal cancer, 215
PIP, 70
P13-K activation, 181
Population effects, 208

Cambridge University Press
 052182091X - Bacterial Protein Toxins: Role in the Interference with Cell Growth Regulation

Edited by Alistair J Lax

Index

[More information](#)

- Rho activation, 181
- Signalling effects, 175–182
- T cell involvement, 183
- Virulence factors, 172–173
- Hepatocyte growth factor (HGF), 180
- Histidine decarboxylase
 - Helicobacter* activation of, 176
- HUVECs, 17, 90
- Hyperplasia
 - Endothelial hyperplasia due to *Bartonella*, 83
- Hypochlorhydria, 209–211
 - Bacterial growth due to, 207
 - Pancreatic cancer, 218
- ICAM-1, 91
 - Bartonella* effects on, 96
- Inflammation
 - Apoptosis and, 132
 - Bartonella* infection, 83
 - Cancer and, 4, 185
 - Helicobacter* and, 170
- Injectisome, 119
- Inositol trisphosphate (IP₃)
 - Calcium release, 12
- Integrin
 - Osteoclast adherence, 151
 - Rho activation and signalling, 35
- Jun kinase (JNK), 18, 132
 - Activation by RANKL, 150
 - CNF activation, 42
 - Induction by *Salmonella* SopE, 122
 - PMT and, 19
 - Rac, 36
 - VEGF activation, 101
- Kaposi's sarcoma, 83
 - Similarity of lesions to bacillary angiomatosis, 105
- Leucine-rich repeat (LRR) proteins, 136
- Leukaemia inhibitory factor (LIF), 70
- Lignins
 - Anticarcinogen, 205
- Lung cancer
 - Tuberculosis link, 218
- Macrophage colony-stimulating factor (MCSF), 149
- Matrix metalloproteinase-3 (MMP-3)
 - Helicobacter* increases, 178
- Metabolites
 - Carcinogenic, 202
- Metalloprotease
 - EGF receptor transactivation, 177
- Mitogen-activated protein kinase (MAPK)
 - Inhibition by SAGP, 69
- Motogenic response
 - Helicobacter*, 179–182
 - Helicobacter* TFSS required for, 180
- Mutation
 - Role in cancer, 200
- Mycotoxins, 201
 - As anti-cancer agents, 201
- Myocardial hypertrophy
 - PMT and, 20
- NF- κ B, 132
 - Activation by RANKL, 150
 - Bartonella* and, 98
 - Helicobacter* activation, 172, 174
 - Introduction, 132
 - Salmonella* SspH1, 136
 - Shigella* IpaH, 98
- N-nitroso compounds (NNC), 202–203
- Normal bacterial flora
 - Protective role, 199
- Oesophageal cancer
 - Helicobacter pylori* link, 215
- Oroya fever, 86
- Osteoblasts, 25
 - Introduction, 148–149
 - PMT interaction with, 156–158
- Osteocalcin, 149
 - Down regulation by PMT, 157
- Osteoclasts, 149–151
 - PMT activation, 161
 - PMT inhibition, 161
 - PMT interaction with, 158–161
- Osteopetrosis, 148
- Osteopontin, 151
- Osteoporosis, 148
- Osteoprotegerin, 151

- p53, 58
Helicobacter and, 183, 184
- PAK
 Activation by *Bartonella*, 98
- Pancreatic cancer, 218–219
- Pasteurella multocida* toxin (PMT)
 DNT homology, CNF homology, 43
- Pasteurella multocida*, 7, 25
- Pasteurella multocida* toxin (PMT), 7–27
 As a tool, 13, 20
 Atrophic rhinitis, 7, 24–25
 Bombesin interaction with, 12
 Bone loss due to, 155–161
 Cancer, 25
 Cell signalling, 10
 CNF homology, 22
 Domain architecture, 22–24
 Facilitation of bombesin signalling, 13
 G₁₁ uninvolved, 14
 Gene, 22
 G_q activation, 13–14
 G_{αq} tyrosine phosphorylation induced by PMT, 21
 Intracellular action, 9–10
 Lethality, 25
 Mitogen, 7–9, 25
 Osteoblasts and, 156–158
 Osteoclasts and, 156–161
 Phospholipase C activation, 11–14
 Protein kinase C activation, 12, 20
 RANKL, 159
 Receptor, 10
 Rho activation, 16–17
 Rho and, 156
 Signalling and, 156
 Target, 21
 Transendothelial permeability, 17
 Variable mitogenicity, 20
- Pathogenicity island (PAI)
cag, 169
- Peptic ulcer
 Cancer linked to, 209–210
- Periodontal disease, 147
A. actinomycetemcomitans, 64
- Pernicious anaemia (PA)
 Cancer link, 209, 210
- Peroxisome proliferator-activated receptor (PPAR), 174
Helicobacter induced apoptosis, 184
- Phospholipase
 Absence in C57Bl/6 mice, 171
 ExoU, 125
P. aeruginosa, 135
 Phospholipase A₂ activation by
Helicobacter, 176
- Phytoestrogens, 205–206
- PI3 kinases
 Cell cycle control, 58
 Rho activation, 35
- Plants
 Anticarcinogens, 205–206
- PMT
 See *Pasteurella multocida* toxin
- Polycyclic aromatic hydrocarbon
 Detoxification, 204
- Polycyclic aromatic hydrocarbon (PAH)
 As carcinogens, 204
- Population
 Link to cancer incidence, 206
- Prevotella intermedia*, 70
- Proliferation
Helicobacter induced, 170
Helicobacter induced proliferation and *cag* status, 173
 Rho, 35–37
- Prostate
 Disease and CNF, 44–45
- Prostate cancer
 Phytoestrogen protection against, 205
- Prostatitis
E. coli infection and, 207
- Protein kinase C (PKC)
 Activation, 12
 Mycobacterial stimulation, 218
 PMT activation, 12
 PMT Erk phosphorylation, 19
- Pseudomonas aeruginosa*
 ExoS effector, 125–127
 ExoT effector, 127
 ExoU and cell death, 135
 ExoY, 136
 TTSS, 117

Cambridge University Press
 052182091X - Bacterial Protein Toxins: Role in the Interference with Cell Growth Regulation

Edited by Alistair J Lax

Index

[More information](#)

- Ra1A
 Action of ExoS, 127
- Rab
 Action of ExoS, 127
 Osteoclast function, 162
- Rac, 18, 33
 Degradation, 42
 Introduction, 14
 PAK, 35
 Proliferation and, 36
 Rho antagonism, 35
- Rap1B
 Action of ExoS, 127
- Ras
 Action of ExoS, 127
C. sordellii activation of, 38
 Introduction, 18
 Osteoclast survival, 162
- Receptor activator of NF- κ B (RANKL)
 PMT and, 159
- Receptor activator of NF- κ B ligand (RANKL), 149
- RGD, 151
- Rho
Bartonella and, 81, 92–95, 98–99
 Bone and, 153–162
 C3 target, 3
 Cell cycle, cell transformation, 34
 Cell transformation, 36
 GAP activity of YopE on RhoA, 124
 ICAM-1, 107
 Immunity and, 107–108
 Importance in bone resorption, 161
 Introduction, 14–15, 33–34, 119–120, 153–154
 Motility, role in 6
 Osteoblast differentiation, 158
 Osteoclasts and, 161–162
 PMT and, 16–17, 156
 Proliferation and, 35–37
 Regulation and adhesion, 107
 Rho A in erythrocytes, 97
 Rho effectors, 34–35
Shigella type III effectors, 123–128
 Toxin targets, 227
 Toxins that activate, 39
 Toxins that inactivate, 37–38
 Type III effectors, 120
 VEGF activation, 101
- Rho kinase, 15, 34–35
 Myosin light chain, 35
 PMT and, 16, 17
 Rac, 35
 RNA interference (RNAi), 180
- SAGP, 69
Salmonella, 120
 Effectors, 39
 SipA effector, 122
 SipB and apoptosis, 134–135
 SipB effector and cell death, 131
 SipC effector, 122
 SopB effector, 122
 SopB effector and inositol phosphatase, 130–131
 SopE, 93
 SopE effector, 121
 SPI effectors, 121–122
 SPI-2 effectors, 136
 SptP action of JNK and ERK, 130
 SptP effector, 122, 130
 SspHs leucine rich repeat (LRR) proteins, 136
 TTSS, 117
 TTSS effectors and signalling, 120–122
 TTSS effectors that affect Rho, 120–122
- Salmonella typhi*
 Carriers and cancer 9
 Infection and gallbladder cancer, 214
- Samonella*
 Other type III effectors, 136
 SPI-2, 135
- Severe combined immune deficiency disorder (SCID), 183
- Shigella*, 120
 CDT, 59, 64
 IpaA, 123
 IpaB, 123, 131, 134
 IpaC, 123
 IpaHs leucine rich repeat (LRR) proteins, 136
 IpgD, 131

- Shigella* (cont)
 TTSS, 117
 TTSS effectors that affect Rho, 123
 VirA effector, 123
- Sickle-cell anemia, 91
- Signalling
 Bone resorption and, 151–152
Helicobacter induced, 169, 175–182
 Toxins targets, 3–4, 227
 Type III effectors that interfere with, 119–136
- Small interfering RNA (siRNA), 180
- Src
 Activation by PMT, 15
- STa, 2, 69
- STI, 70
- Streptococcus pyogenes*, 69
- Structure
 CNF, 41
- T cells
Helicobacter induced pathology and, 183
- Tartrate resistant acid phosphatase (TRAP), 151
- TNF-receptor-associated factor (TRAF)
 Activation by RANKL, 150
- Toxin chimeras
 C3, 38
- Toxins
 Bone and, 153–162
 Introduction and history, 1
- Transendothelial permeability
 PMT and, 17
- Transgenic mice
Helicobacter research, 182
- Transgenic mouse model
Helicobacter research, 172
- Transglutamination
 Rho transglutamination by DNT, 43
- Translocation
 Translocation via low pH step, 10
- Transverse urea gradient gels, 10
- Triple membrane passing signal (TMPS)
 EGF receptor activation, 177
 Over-expression in gastric cancer, 179
- Tryptophan
 Metabolism linked to cancer, 202
- TTSS
 Cell death, 131
- Tuberculosis (TB)
 Lung cancer and, 218
- Tumour promoters
 Toxins as, 229
- Type III effectors
 Action on bacterial entry, 120–128
 Action on Rho, 119–128
 Of unknown function, 136
- Type III secretion, 2–3, 117–136
 Introduction, 117–119
 kinases, 128–131
 phosphatases, 128–129
- Type IV secretion
Bartonella and, 95
Helicobacter, 179
- Type IV secretory
Helicobacter, 173
- Typhoid
 Cancer link, 215
 Carriers and pancreatic cancer, 219
- Tyrosine phosphatases
 YopH, 129
- Tyrosine phosphorylation
 Inhibitor as anticarcinogen, 205
 PMT induction, 15–16
 Tyrosine phosphorylation of $G_{\alpha q}$, 21
- Ulceration
Helicobacter, 169
- Urinary tract
 Cancer, 206–207
 Disease and CNF, 44–45
- Vascular Epithelial Growth Factor (VEGF), 100–106
 Apoptosis, 102
 Block of NF- κ B, 105
 Endothelial mitogen, 101
 FAK Src, 102
 Hypoxia, 100
 Immune function, 104
 Inflammation, 104

Cambridge University Press

052182091X - Bacterial Protein Toxins: Role in the Interference with Cell Growth Regulation

Edited by Alistair J Lax

Index

[More information](#)

- Nitric oxide (NO), 103
- p38 MAPK, 102
- Paxillin, 102
- Verotoxin (VT), 69
- Verruga, 86
 - Bartonella* and, 82
- Vitronectin, 151
- Yersinia*
 - TTSS, 117
 - Yops, 118–119
 - YopE, 124
 - YopH, 129–130
 - YopH and immune function, 130
 - YopH interaction with P13K, 129
 - YopJ
 - Apoptosis caused by, 132
 - YopJ and inflammation, 132–134
 - YopJ and signalling
 - YopJ/P and cell death, 131
 - YopM leucine-rich repeat (LRR) proteins, 136
 - YopT effector, 124–125
 - YpkA/YopA effector, 131
- Yops, 118–119